Trim39-RPP21: A promising protein target for TRIM39 and cancer therapy

Target Name: TRIM39-RPP21

NCBI ID: G202658

TRIM39-RPP21

Trim39-RPP21: A promising protein target for TRIM39 and cancer therapy

TRIM39 and RPP21 are key proteins that play crucial roles in the regulation of DNA damage repair. TRIM39, also known as DNA damage-inducible gene 39, is a non-coding RNA-protein hybrid that was discovered as a potential drug target for various diseases, including cancer. RPP21, also known as DNA repair protein 21, is a non-coding RNA that is involved in the repair of DNA double-strand breaks. The identification of TRIM39 and RPP21 as potential drug targets has generated a significant amount of interest in the field of pharmacology and cancer treatment.

TRIM39 function and role in DNA damage repair

TRIM39 is a non-coding RNA-protein hybrid that was discovered as a potential drug target for various diseases, including cancer. It is expressed in various tissues and cells and is involved in the regulation of DNA damage repair. TRIM39 is a DNA damage-inducible gene that is activated in response to DNA damage, such as UV radiation, radiation, or chemical stress. When TRIM39 is activated, it induce the expression of various genes involved in DNA damage repair.

One of the critical functions of TRIM39 is its role in the regulation of DNA double-strand break repair. Double-strand breaks are one of the most common types of DNA damage that can occur during the course of DNA replication. These breaks can lead to the loss of genetic information and the development of genetic mutations, which can lead to the development of diseases such as cancer.

TRIM39 is involved in the regulation of DNA double-strand break repair by activating various genes involved in the repair process. These genes include DNA repair enzyme (DRE), which is responsible for repairing double-strand breaks, and non-homologous end joining (NHEJ) repair, which is another type of DNA repair process that can repair double-strand breaks.

In addition to its role in DNA double-strand break repair, TRIM39 is also involved in the regulation of DNA base repair. base repair is a critical process that ensures that the base-pair integrity of the DNA is maintained even in the presence of damage. TRIM39 is involved in the regulation of base repair by activating genes involved in the repair process, such as base repair enzyme (BRE), which is responsible for repairing single-strand DNA base damage.

TRIM39 as a drug target

The identification of TRIM39 as a potential drug target has generated a significant amount of interest in the field of pharmacology. TRIM39 has been shown to be involved in various diseases, including cancer, and its activation in response to DNA damage has been linked to the development of these diseases.

TRIM39 has been shown to be involved in the regulation of cell cycle progression, which is the process by which cells grow, divide, and replicate their genetic material. TRIM39 has been shown to play a role in the regulation of the G1 phase of the cell cycle, which is the stage of cell growth and preparation for cell division.

In addition to its role in cell cycle progression, TRIM39 has also been shown to be involved in the regulation of apoptosis, which is the process by which cells die and are removed from the body. TRIM39 has been shown to play a role in the regulation of apoptosis by activating genes involved in the process.

TRIM39 has also been shown to be involved in the regulation of inflammation. TRIM39 has been shown to play a role in the regulation of the inflammatory response by activating genes involved in the process.

In conclusion, TRIM39 is a non-coding RNA-protein hybrid that is involved in

Protein Name: TRIM39-RPP21 Readthrough

The "TRIM39-RPP21 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRIM39-RPP21 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets